**Cases pending with drug price liability review committee**

516. SHRI UDAY PRATAP SINGH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) the details of cases pending with the Drug Price Liability Review Committee; and

(b) the names of the companies and the amount quantified?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI RAM VILAS PASWAN): (a) As on date, there are two cases pending with the Drug Prices Liabilities Review Committee (DPLRC) pertaining to M/s. S.G. Pharmaceuticals Ltd and M/s Geoffry Manners & John Wyeth Ltd. for quantification of DPEA liability of these companies. In addition, there are 26 cases pending with the Committee which cannot be taken up by the DPLRC because of the stay dated 30.6.1997 granted by the Hon'ble Bombay High Court in writ petition filed by the Indian Drugs Manufacturer's Association (IDMA) & others restraining the Department and its committees from determining fresh liabilities.

(b) The names of the companies and the amount quantified by the DPLRC is given in statement.

***Statement***

*Name of the Company and amount of liability quantified by the DPLRC.*

(Rs. in lakhs)

| Sl. No. | Name of the Company | Name of the bulk drug | Amount of liability qualified by the DPLRC |
|---|---|---|---|
| (1) | (2) | (3) | (4) |
| 1 | M/s Merind Ltd | Dexamethasone | 6772.8 |
| 2 | M/s Biochem Pharma Industries | Rifampicin | 99.76 |
| 3 | M/s Lupin Laboratories | Rifampicin | 1065.09 |
| 4 | M/s Unique Pharmaceuticals | Oxyphenabutazone | 591,05 |
| 5 | M/s Ambalal Sarabhai Enterpises | Amoxycillin Trihydrate | 84.13 |
| 6 | M/s Gufic Ltd | Amoxycillin Trihydrate | 73.86 |
| 7 | M/s Lyka Labs | Ampicillin Trihydrate | 70.37 |
| 8 | M/s Unique Pharma Labs Ltd | Metronidazole | 461.47 |
| 9 | M/s Ranbaxy Laborafories Ltd. | Ampicillin Trihydrate | 416.84 |
| 10 | M/s Lyka Labs | Rifampicin | 148.38 |
| 11 | M/s Lyka Labs Ltd | Ethambutol | 38.50 |
| 12 | M/s Dolphin Labs Ltd | Amoxycillin Trihydrate | 51.53 |

| (1) | (2) | (3) | (4) |
|---|---|---|---|
| 13 | M/s Astra-IDL Ltd | Ibuprofen | 174.86 |
| 14 | M/s Ranbaxy Labs Ltd | Rifampicin | 203.00 |
| 15 | M/s Themis Chemicals | Rifampicin | 126.07 |
| 16 | M/sCipla Ltd | Metronidazole | 22.81 |
| 17 | M/s Lyka Labs Ltd | Amoxycillin Trihydrate | 13.95 |
| 18 | M/s Knoll Pharmaceutical | Ibuprofen | 346.64/57.67@ |
| 19 | M/s Themis Chemicals | Ethamubtol | 200.00 |
| 20 | M/s Lyka Labs | Fluocinolone Acetonide | 1804.65/Nil@ |
| 21 | M/s Dolphin Labs Ltd | Metronidazole | 28.66 |
| 22 | M/s Tamil Nadu Dadha | Calcium Lactate | 130.34/120.90@ |
| 23 | M/s Boehringer Mannheim (India) Ltd. | Euglucon Tabs | 313.17 |
| 24 | M/s U.S. Vitamins Ltd. | Doxycycline | 132.62/125.19@ |
| 25 | M/s Dolphin Labs Ltd. | Sulphamethaxazole & Trimethoprim | 54.20/11.45@ |
| 26. | M/s Cyanamid (India) (Now M/s Wyeth Lederle Ltd.) | Dimethyl Chloro-Tetracycline Hydrochloride etc. | 4304.16/4274.72@ |

@There is difference of opinion among Members of DPLRC.

**Impact of new Patents Act on domestic Pharmaceutical sector**

517. SHRI MANOJ BHATTACHARYA:
SHRI C. RAMACHANDRAIAH:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether the new Patents Act passed recently has made any impact on the domestic pharmaceutical sector;

(b) if so, the details thereof; and

(c) the measures adopted to prevent the anticipated hike in price of life-saving drugs and make them available at affordable prices?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI RAM VILAS PASWAN): (a) and (b) It is too early to know the effect of the new patent regime on the prices of drugs. However, the National Pharmaceutical Pricing Authority has not received any report of abnormal increase in the prices of drugs or their non-availability after the said amendment.

(c) The patent law in the country provides for a strong and comprehensive set of safeguards including provisions to ensure